Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease

Inebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.
Medscape Medical News

source https://www.medscape.com/viewarticle/inebilizumab-mitigates-flare-risk-igg4-related-disease-2024a1000apn?src=rss